Previous 10 | Next 10 |
BOSTON, March 04, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the UK Medic...
BOSTON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the U.S. Food...
2024-02-11 18:00:00 ET Summary PTC Therapeutics has a diverse portfolio and pipeline of drugs, including a broader DMD treatment. The company has not fully expanded its revenue-generating products geographically and is in the process of making the necessary submissions to do so. ...
2024-02-07 10:00:01 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Lilly, Zoetis, Abbott least shor...
2024-02-07 07:45:11 ET More on PepGen PepGen: Long Road Ahead PepGen stock soars after rival Sarepta reports data for DMD drug Seeking Alpha’s Quant Rating on PepGen Historical earnings data for PepGen Financial information for PepGen ...
BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the pricing of an ...
A look at the top 10 most actives in the United States Remark Holdings Inc. (MARK) rose 264.4% to $1.25 on volume of 238,216,008 shares Advanced Micro Devices Inc. (AMD) fell 3.2% to $172.06 on volume of 122,265,677 shares Phunware Inc. (PHUN) fell 1.0% to $0.2893 on volume of 119,416,884...
2024-01-30 12:25:46 ET More on PepGen PepGen: Long Road Ahead Seeking Alpha’s Quant Rating on PepGen Historical earnings data for PepGen Financial information for PepGen Read the full article on Seeking Alpha For further details see: ...
2024-01-30 11:50:46 ET Gainers: Neximmune ( NEXI ) +163% . Pixelworks ( PXLW ) +47% . PepGen ( PEPG ) +37% . Rail Vision Ltd ( RVSN ) +36% . Bit Origin Ltd ( BTOG ) +34% . Vivos Therapeutics ( VVOS ) +32% . GRI Bi...
2024-01-20 03:41:05 ET Summary PepGen is using exon skipping therapies to address muscular dystrophy conditions, specifically Duchenne muscular dystrophy (DMD) and Myotonic dystrophy type 1 (DM1). They are developing PGN-EDO51 and PGN-EDODM1. The market sizes for these therapi...
News, Short Squeeze, Breakout and More Instantly...
2024-07-06 15:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the expansion of its executive team with the appointments of...
Michelle Mellion, M.D., promoted to Chief Medical Officer Hayley Parker, Ph.D., promoted to Senior Vice President, Global Regulatory Affairs PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of t...